These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 9148408)
1. Publishing sensitive data: who calls the shots? Long-suppressed study finally sees light of day. Vogel G Science; 1997 Apr; 276(5312):525-6. PubMed ID: 9148408 [No Abstract] [Full Text] [Related]
7. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. Brantigan CO JAMA; 1997 Sep; 278(11):897; author reply 898-9. PubMed ID: 9302236 [No Abstract] [Full Text] [Related]
8. Research suppressed for seven years by drug company. Wise J BMJ; 1997 Apr; 314(7088):1145. PubMed ID: 9146378 [No Abstract] [Full Text] [Related]
9. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. Birnbaum R JAMA; 1997 Sep; 278(11):897-8; author reply 898-900. PubMed ID: 9302239 [No Abstract] [Full Text] [Related]
10. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. Lankin KM JAMA; 1997 Sep; 278(11):897; author reply 898-900. PubMed ID: 9302238 [No Abstract] [Full Text] [Related]
11. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. Bell BM JAMA; 1997 Sep; 278(11):896; author reply 898-9. PubMed ID: 9302234 [No Abstract] [Full Text] [Related]
12. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. Donohoe M JAMA; 1997 Sep; 278(11):896-7; author reply 898-9. PubMed ID: 9302235 [No Abstract] [Full Text] [Related]
13. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. Gordon BD JAMA; 1997 Sep; 278(11):896; author reply 898-9. PubMed ID: 9302233 [No Abstract] [Full Text] [Related]
14. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. St Germain DL; Ridgway EC JAMA; 1997 Sep; 278(11):895-6; author reply 898-9. PubMed ID: 9302232 [No Abstract] [Full Text] [Related]
15. Reassurance about bioequivalence of generic thyroxine. Feek CM N Z Med J; 1992 Jan; 105(926):21. PubMed ID: 1549275 [No Abstract] [Full Text] [Related]
16. [Preventable problems in thyroid hormone substitution therapy. The risks of brand change are unpredictable]. MMW Fortschr Med; 2010 Jun; 152(22):46-7. PubMed ID: 20590034 [No Abstract] [Full Text] [Related]
17. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. Dong BJ; Hauck WW; Gambertoglio JG; Gee L; White JR; Bubp JL; Greenspan FS JAMA; 1997 Apr; 277(15):1205-13. PubMed ID: 9103344 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. DeGroot LJ JAMA; 1997 Sep; 278(11):895; author reply 898-9. PubMed ID: 9302231 [No Abstract] [Full Text] [Related]
19. [Levothyroxine and the problem of interchangeability of drugs with narrow therapeutic index]. Ward LS Arq Bras Endocrinol Metabol; 2011 Oct; 55(7):429-34. PubMed ID: 22147090 [TBL] [Abstract][Full Text] [Related]
20. I'm taking a generic version of Synthroid and I don't seem to feel as well as when I took the brand-name version. Is there a difference between the two? Mayo Clin Womens Healthsource; 2006 Feb; 10(2):10. PubMed ID: 16404339 [No Abstract] [Full Text] [Related] [Next] [New Search]